ESTEEM 2 研究表明与安慰剂相比,接受阿普米司特治疗的头皮银屑病患者,在第16周达到ScPGA 0/1的患者比例为
A、46.5% vs 17.5%
B、40.9% vs 17.2%
C、48.6% vs 15.5%
D、52.1% vs 10.2%
发布时间:2025-07-15 22:39:04
A、46.5% vs 17.5%
B、40.9% vs 17.2%
C、48.6% vs 15.5%
D、52.1% vs 10.2%